Briefing

Featured article

Johnson & Johnson agrees to acquire Ambrx Biopharma for $2bn

Also in this section

News in Numbers

Latest News

Latest Deals

Project Updates

Trends & Insight

03/07/2024 14:25:30
  • Home | Inside the world of priority review vouchers where time is money
  • Editor's letter
  • Contents
  • Mimotopes Company Insight
  • Mimotopes
  • Briefing
  • News in Numbers
  • Latest News
  • Latest Deals
  • Project Updates
  • Trends & Insight
  • Molnar-Institute Company Insight
  • Molnar-Institute
  • Lactalis Ingredients
  • In Depth
  • Inside the world of priority review vouchers where time is money
  • Quality and sustainability: The balancing act for pharma manufacturing
  • 2023 in review: Cancer vaccines dose up on advances with tailored approaches
  • Diversity and ePROs: Still siloed concepts in the era of DCTs?
  • Q&A: Tackling the rise of fake anti-obesity drugs on the market
  • Patching the problem of EU drug shortages
  • Out-of-spec cell therapy manufacturing: an ethical dilemma for CDMOs and doctors
  • Nipro
  • phasetwo
  • Thematic Take
  • Thematic Take: contents
  • Foreword: What’s next for the Internet of Things
  • An introduction to the Internet of Things
  • The digital ecosystem of the IoT
  • Timeline: Internet of Things
  • The impact of IoT on the pharma industry
  • Applications of IoT in the pharma industry
  • Latest news: IoT in pharma
  • Analyst Q&A: IoT in pharma
  • Bupa leverages unique position to develop IoT and AI features
  • IoT innovation: Leading companies in microneedles for transdermal drug delivery
  • IoT in the pharmaceutical industry: analysing innovation, investment and hiring trends
  • GlobalData Thematic Intelligence
  • Sponsored Supplements
  • Avenga Company Insight
  • Listings
  • Events
  • Innovation Rankings
  • Buyer's Guides
  • Next issue
01/17/2024 00:00:00